Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein

Simple item page
cg.authorship.typesCGIAR and developing country instituteen
cg.authorship.typesCGIAR and advanced research instituteen
cg.contributor.affiliationKenya Medical Research Instituteen
cg.contributor.affiliationUniversity of Oxforden
cg.contributor.affiliationLondon School of Hygiene and Tropical Medicineen
cg.contributor.affiliationInternational Livestock Research Instituteen
cg.contributor.crpAgriculture for Nutrition and Health
cg.contributor.donorWellcome Trusten
cg.contributor.donorOak Foundationen
cg.contributor.donorMedical Research Council, United Kingdomen
cg.coverage.countryKenya
cg.coverage.iso3166-alpha2KE
cg.coverage.regionAfrica
cg.coverage.regionEastern Africa
cg.creator.identifierBernard Bett: 0000-0001-9376-2941
cg.howPublishedFormally Publisheden
cg.identifier.doihttps://doi.org/10.1016/j.isci.2020.101669en
cg.isijournalISI Journalen
cg.issn2589-0042en
cg.issue11en
cg.journaliScienceen
cg.reviewStatusPeer Reviewen
cg.subject.ilriANIMAL DISEASESen
cg.subject.ilriEPIDEMIOLOGYen
cg.subject.ilriHUMAN HEALTHen
cg.subject.ilriRVFen
cg.volume23en
dc.contributor.authorWright, D.en
dc.contributor.authorAllen, E.R.en
dc.contributor.authorClark, M.H.A.en
dc.contributor.authorGitonga, J.N.en
dc.contributor.authorKaranja, H.K.en
dc.contributor.authorHulswit, R.J.G.en
dc.contributor.authorTaylor, I.en
dc.contributor.authorBiswas, S.en
dc.contributor.authorMarshall, J.en
dc.contributor.authorMwololo, D.en
dc.contributor.authorMuriuki, J.en
dc.contributor.authorBett, Bernard K.en
dc.contributor.authorBowden, T.A.en
dc.contributor.authorWarimwe, G.M.en
dc.date.accessioned2020-10-26T13:06:12Zen
dc.date.available2020-10-26T13:06:12Zen
dc.identifier.urihttps://hdl.handle.net/10568/109976
dc.titleNaturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoproteinen
dcterms.abstractRift Valley fever (RVF) is a viral hemorrhagic disease first discovered in Kenya in 1930. Numerous animal studies have demonstrated that protective immunity is acquired following RVF virus (RVFV) infection and that this correlates with acquisition of virus-neutralizing antibodies (nAbs) that target the viral envelope glycoproteins. However, naturally acquired immunity to RVF in humans is poorly described. Here, we characterized the immune response to the viral envelope glycoproteins, Gn and Gc, in RVFV-exposed Kenyan adults. Long-lived IgG (dominated by IgG1 subclass) and T cell responses were detected against both Gn and Gc. However, antigen-specific antibody depletion experiments showed that Gn-specific antibodies dominate the RVFV nAb response. IgG avidity against Gn, but not Gc, correlated with nAb titers. These data are consistent with the greater level of immune accessibility of Gn on the viral envelope surface and confirm the importance of Gn as an integral component for RVF vaccine development.en
dcterms.accessRightsOpen Access
dcterms.audienceScientistsen
dcterms.bibliographicCitationWright, D., Allen, E.R., Clark, M.H.A., Gitonga, J.N., Karanja, H.K., Hulswit, R.J.G., Taylor, I., Biswas, S., Marshall, J., Mwololo, D., Muriuki, J., Bett, B., Bowden, T.A. and Warimwe, G.M. 2020. Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein. iScience 23(11): 101669.en
dcterms.issued2020-11
dcterms.languageen
dcterms.licenseCC-BY-NC-ND-4.0
dcterms.publisherElsevieren
dcterms.subjectimmunologyen
dcterms.subjectvirologyen
dcterms.subjectrift valley fever virusen
dcterms.typeJournal Article

Files

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ILRI articles in journals
CRP A4NH outputs
ILRI animal and human health program outputs (2017–2024)